Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Cryptocurrencies pulled back after President Trump's inauguration address, in which he didn't mention crypto. That weighed on shares of MicroStrategy, the software company-turned-bitcoin buyer, in ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...
Tesla stock rises even as President Donald Trump plans to roll back federal electric-vehicle production targets, Apple stock ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.